Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSolara active pharma

    Solara Active Pharma

    Jump to

    • USFDA inspection at Solara's Visakhapatnam facility completed without any observations

      Solara has two FDA inspected manufacturing sites (Puducherry and Visakhapatnam) for Ibuprofen substance.

    • Solara Active Pharma spurts 9% on heavy volumes

      The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings — Ibuprofen, Favipiravir and Gabapentin

    • Solara Active Pharma Q4 PAT seen up 223.6% YoY to Rs. 57.6 cr: Sharekhan

      Net Sales are expected to increase by 35.4 percent Y-o-Y (down 5.8 percent Q-o-Q) to Rs. 401.9 crore, according to Sharekhan.

    • Solara Active Pharma shares jump 7% after broad approves amalgamation

      Solara Active Pharma Sciences approved the amalgamation of Aurore Life Science, Empyrean Lifesciences and Hydra Active Pharma Sciences with itself.

    • Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall

      "We understand from Mylan NV's press release dated January 8, 2020, that Mylan Pharmaceuticals has initiated a voluntary recall of three lots of Nizatidine Capsules, USP (150 mg and 300 mg strengths) due to detected trace amounts of impurity...," Solara Active Pharma Sciences in a filing to BSE.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347